Abstr 605 PD-022
•Chemotherapy and chemoradiation are the main options in LAPC •Surgery becomes feasible only in a small proportion of patients after neoadjuvant therapy.
•FOLFIRINOX is an active treatment in advanced pancreatic cancer.
• This is a prospective single-arm trial.
• Main inclusion criteria were: LAPC (cT4, cN0-1, cM0) considered unresectable according to definition of the American Hepato-Pancreato-Biliary Association consensus conference); ECOG Performance Status 0-1; age 18-75 years • Patients were treated with modified FOLFOXIRI (irinotecan 150 mg/sqm, oxaliplatin 85 mg/sqm, folinate 200 mg/sqm, 5-fluorouracil 2800 mg/sqm in 48h) every 2 weeks.
• Tumor assessment was performed by CT scan every 8 weeks and multidisciplinary team evaluated patients after every CT scan.
Background

Materials and Methods
Results
•Chemotherapy with FOLFOXIRI seems feasible and active in LAPC •Induction CT may allow achieving resectability in some patients
Conclusions
•From 2008 to 2015 we enrolled a total of 59 patients (Table 1) .
• Response Rate was 34%, disease control rate 88%.
• After chemotherapy 28 patients (47%) underwent radical surgery
• Seventeen (61%) patients received total pancreatectomy, 8 (28%)pancreaticoduodenectomy and 3 (11%) left pancreatectomy
• Details about vascular resection are reported in Table 2 .
• FOLFOXIRI is a similar regimen, with lower dose of irinotecan and no 5-fluorouracil bolus, that has shown good activity in advanced colorectal cancer.
• We prospectively evaluated the activity of FOLFOXIRI in LAPC.
• If tumor was judged resectable, patients underwent surgery after 4-6 weeks from last chemotherapy cycle, otherwise after 8 cycles radiotherapy was evaluated.
• Primary endpoint is rate of secondary radical surgery • Progression-free survival (PFS), overall survival (OS), response rate (RR) and safety were secondary objectives.
• Treatment will be considered of interest if it shows an increase in surgical procedures from an expected 30% to at least 45% and in particular if 27 patients will be resected over 67 enrolled (alpha and beta errors: 0.05 and 0.10, respectively). •Median number of FOLFOXIRI cycles: 8 (range 2-14).
•After the first 34 patients, considering good tolerability, protocol was amended and we started to use classic schedule of FOLFOXIRI (irinotecan 165 mg/sqm and 5FU 3200 mg in 48h)
•Main grade 3-4 toxicities during chemotherapy were neutropenia (46%), asthenia (15%) and diarrhea (8%). There were no significant differences in toxicities between the two schedules
• Consort diagram of the study is reported in Figure 1 .
pts enrolled 52 pts (88%) SD/RP
•7 pts (12%) experienced disease progression during chemotherapy
• 23 pts not resectable •1 patient waiting for surgery 28 pts (47%) underwent surgery Celiac Axis 1 4
Hepatic Artery 6 21
Portal Vein/Superior Mesenteric Vein 25 89 Table 2 • Early post-operative mortality rate was 8%
• Accrual was stopped after the number of planned resections was reached • Median follow up was 26.9 months • In the whole population median PFS was 11.9 months, median OS was 15.3 months and 2-years OS rate was 22.5% ( Figure 2a) • In resected patients median PFS was 14.9 months, median OS was 19.8 months and 2-years OS rate was 35% (Figure 2b) •Although longer follow up is needed, results in terms of PFS and OS are encouraging caterinavivaldi@gmail.com Clinical Pancreatic Cancer
